Management of incomplete remission and treatment resistance in first-episode psychosis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 12, 2008, Pages 2039-2051

  Lambert, Martin ^a   Naber, Dieter ^a   Huber, Christian G ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Incomplete remission; Pseudo resistance; Psychosis; Therapy; Treatment resistance

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HEMOPOIETIC GROWTH FACTOR; LAMOTRIGINE; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

AGRANULOCYTOSIS; BIPOLAR DISORDER; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; DECISION MAKING; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FIRST EPISODE PSYCHOSIS; HUMAN; HYPOTENSION; LEUKOPENIA; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; NEUTROPENIA; OBESITY; PATIENT COMPLIANCE; PSYCHOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REMISSION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; HUMANS; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; RECURRENCE; REMISSION INDUCTION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT FAILURE;

EID: 50949086593     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.12.2039     Document Type: Review

References (73)

1. Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 2008;9(12):2027-38
2. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
3. Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia. Expert Rev Neurother 2004;4(4):705-23
4. Buckley PF, Wiggins LD, Sebastian S, Singer B. Treatment-refractory schizophrenia. Curr Psychiatry Rep 2001;3(5):393-400
5. Schimmelmann BG, Conus P, Edwards J, et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005;66(10):1239-46
6. Andreasen NC, Carpenter WT JR, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-9
7. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv 2005;56:735-42
8. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227-40
9. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
10. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(Suppl 22):7-11
11. Nierenberg AA, Dececco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9
12. National Institute for Clinical Excellence (editors). Clinical Guideline 1 Schizophrenia Core Interventions in the Treatment and Mangement of Schizophrenia in Primary and Secondary Care. London: National Institute for Clinical Excellence; 2002
13. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 249-440
14. Royal Australian and New Zealand College of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39(1/2):1-30
15. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 525-612
16. Royal Australian And New Zealand College Of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38(5):280-305
17. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 440-524
18. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-80
19. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112(2):141-8
20. Lambert M, Conus P, Naber D, et al. Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-fine trial of risperidone. Int J Psychiatry Clin Pract 2005;9(4):244-50
21. Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005;38(5):206-13
22. Pantelis C, Lambert TJ. Managing patients with 'treatment-resistant' schizophrenia. Med J Aust 2003;178(Suppl):S62-6
23. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
24. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004;26(12):1994-2002
25. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160(6):1125-32
26. Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66(2/3):143-50
27. Lindenmayer JP, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63(10):931-5
28. Lambert M, Naber D, editors. Current schizophrenia. Hamburg: Science Press; 2004
29. Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(6):1330-6
30. Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63(5):420-4
31. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158(4):518-26
32. Ciapparelli A, Dell'osso L, Bandettini Di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003;64(4):451-8
33. Pickar D, Bartko JJ. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Am J Psychiatry 2003;160(6):1133-8
34. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159(2):255-62
35. Remington G, Saha A, Chong SA, Shamm C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-72
36. Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002;27(6):1050-5
37. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61(Suppl 8):14-7; discussion 18-9
38. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20(5/6):409-15
39. Williams L, Newton G, Roberts K, et al. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 2002;181:184-7
40. Kämpf P, Agelink MW, Mas R, et al. Amisulpride in addition to dozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003;6(3):64-8
41. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 2005;19(3):301-5
42. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28(2):66-71
43. Lerner V, Libov I, Kotler M, Strous RD. Combination of 'atypical' antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(1):89-98
44. Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000;23(5):284-6
45. Valmaggia LR, Van Der Gaag M, Tarrier N, et al. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. Br J Psychiatry 2005;186:324-30
46. Sensky T, Turkington D, Kingdon D, et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000;57(2):165-72
47. Fitzgerald PB, Benitez J, Daskalaki JZ, et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J Clin Psychopharmacol 2005;25(4):358-62
48. Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):37-47
49. Bowden CL. Treatment options for bipolar depression. J Clin Psychiatry 2005;66(Suppl 1):3-6
50. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161(9):1537-47
51. Kilzieh N, Akiskal HS. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am 1999;22(3):585-607
52. Colom F, Vieta E. A perspective on the use of psychoeducation, cognitive-behavioral therapy and interpersonal therapy for bipolar patients. Bipolar Dis 2004;6(6):480-6
53. Perry A, Tarrier N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318(7177):149-53
54. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60(4):402-7
55. Vieta E. The package of care for patients with bipolar depression. J CJin Psychiatry 2005;66(Suppl 5):34-9
56. Miklowitz DJ, Simoneau TL, George EL, et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000;48(6):582-92
57. Ros S, Aguera L, De La Gandara J, et al. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand Suppl 2005;(428):14-24, 36
58. Quitkin FM, Mcgrath PJ, Stewart JW, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology 1996;15(4):390-4
59. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001;62(Suppl 18):12-7
60. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S
61. Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003;18(11):1013-20
62. Fava M. Augmentation and combination strategies in treatment-resistarit depression. J Clin Psychiatry 2001;62(Suppl 18):4-11
63. Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl 2005;(428):25-31, 36
64. Klein N, Sacher J, Wallner H, et al. Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. CNS Spectr 2004;9(11):823-32
65. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):30-40
66. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):13-21
67. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66(10):1216-20
68. Malhi GS, Berk M, Bourin M, et al. A typical mood stabilizers: a 'typical' role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005;(426):29-38
69. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(Suppl 1):17-25
70. Mcpherson S, Cairns P, Carlyle J. et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005;111(5):331-40
71. Avery DH, Holtzheimer PE III, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006;59(2):187-94
72. Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005;137(1/2):1-10
73. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66(9):1097-104